{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:46:01Z","timestamp":1779925561177,"version":"3.53.1"},"reference-count":21,"publisher":"The Japan Society of Coloproctology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Anus Rectum Colon"],"published-print":{"date-parts":[[2022,1,28]]},"DOI":"10.23922\/jarc.2021-042","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T22:09:35Z","timestamp":1643321375000},"page":"52-57","source":"Crossref","is-referenced-by-count":3,"title":["A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study"],"prefix":"10.23922","volume":"6","author":[{"given":"Akihisa","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Graduate School of Medicine, Gifu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Surgery 1, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Kawasaki Medical School and Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishimaru","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Gastroenterology, Ehime University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Coloproctological Surgery, Juntendo University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Koda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teikyo University Chiba Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Specialized Surgeries, Medical Research Institute, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Second Department of Surgery, School of Medicine, Wakayama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kuramochi","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Tokyo Women's Medical University Yachiyo Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Hepato-Biliary-Pancreatic Surgery, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10009","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68 (6): 394-4.","DOI":"10.3322\/caac.21492"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Van Cutsem E, K\u00f6hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2; 360 (14): 1408-17.","DOI":"10.1056\/NEJMoa0805019"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Li\u00e8vre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006 Apr 15; 66 (8): 3992-5.","DOI":"10.1158\/0008-5472.CAN-06-0191"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mao C, Wu XY, Yang ZY, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep. 2015 Feb 2; 5: 8065.","DOI":"10.1038\/srep08065"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yamada T, Matsuda A, Koizumi M, et al. Liquid biopsy for the management of patients with colorectal cancer. Digestion. 2019; 99 (1): 39-45.","DOI":"10.1159\/000494411"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamada T, Iwai T, Takahashi G, et al. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. Cancer Sci. 2016 Jul; 107 (7): 936-43.","DOI":"10.1111\/cas.12959"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Furuki H, Yamda T, Takahashi G, et al. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer. Eur J Surg Oncol. 2018 Jul; 44 (7): 975-82.","DOI":"10.1016\/j.ejso.2018.01.224"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Takeda K, Yamada T, Takahashi G, et al. Analysis of colorectal cancer-related mutations by liquid biopsy: utility of circulating cell-free DNA and circulating tumor cells. Cancer Sci. 2019 Nov; 110 (11): 3497-509.","DOI":"10.1111\/cas.14186"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. 2014 Nov 1; 135 (9): 2215-22.","DOI":"10.1002\/ijc.28863"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Grasselli J, Elez E, Carat\u00f9 G, et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017 Jun 1; 28 (6): 1294-301.","DOI":"10.1093\/annonc\/mdx112"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Vidal J, Muinelo L, Dalmases A, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017 Jun 1; 28 (6): 1325-32.","DOI":"10.1093\/annonc\/mdx125"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun 28; 486 (7404): 537-40.","DOI":"10.1038\/nature11219"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28; 486 (7404): 532-6.","DOI":"10.1038\/nature11156"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015 Jul; 21 (7): 795-801.","DOI":"10.1038\/nm.3870"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yamada T, Matsuda A, Takahashi G, et al. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. Int J Clin Oncol. 2020 Aug; 25 (8): 1523-32","DOI":"10.1007\/s10147-020-01691-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014 Jul 20; 32 (21): 2240-7.","DOI":"10.1200\/JCO.2013.53.2473"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gao W, Chen Y, Yang J, et al. Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer. Front Genet. 2021 Jan 28; 12: 634642.","DOI":"10.3389\/fgene.2021.634642"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bando H, Kagawa Y, Kato T, et al. A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. Br J Cancer. 2019 May; 120 (10): 982-6.","DOI":"10.1038\/s41416-019-0457-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Toledo RA, Cubillo A, Vega E, et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget 2017; 8 (21): 35289-300.","DOI":"10.18632\/oncotarget.13311"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kim TW, Peeters M, Thomas A, et al. Impact of Emergent Circulating Tumor DNA <i>RAS<\/i> Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. Clin Cancer Res. 2018 Nov 15; 24 (22): 5602-9.","DOI":"10.1158\/1078-0432.CCR-17-3377"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Morelli MP, Overman MJ, Dasari A, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015 Apr; 26 (4): 731-6.","DOI":"10.1093\/annonc\/mdv005"}],"container-title":["Journal of the Anus, Rectum and Colon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/6\/1\/6_2021-042\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T03:14:01Z","timestamp":1643426041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/6\/1\/6_2021-042\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.23922\/jarc.2021-042","relation":{},"ISSN":["2432-3853"],"issn-type":[{"value":"2432-3853","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"article-number":"2021-042"}}